BiotechTube

VSF-173

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Excessive Somnolence

Conditions

Excessive Somnolence

Trial Timeline

— → —

NCT ID
NCT00467441

About VSF-173

VSF-173 is a phase 2 stage product being developed by Vanda Pharmaceuticals for Excessive Somnolence. The current trial status is completed. This product is registered under clinical trial identifier NCT00467441. Target conditions include Excessive Somnolence.

What happened to similar drugs?

2 of 5 similar drugs in Excessive Somnolence were approved

Approved (2) Terminated (1) Active (3)
✅Solriamfetol + PlaceboAxsome TherapeuticsApproved
🔄Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
🔄Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
✅Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
🔄Fibrin Sealant Grifols + EVICELGrifolsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00467441Phase 2Completed

Competing Products

8 competing products in Excessive Somnolence

See all competitors
ProductCompanyStageHype Score
Placebo + PF-03654746PfizerPhase 2
35
JZP-110Jazz PharmaceuticalsPhase 2
32
Solriamfetol + PlaceboAxsome TherapeuticsApproved
40
Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
44
Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
44
Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
32
Fibrin Sealant Grifols + EVICELGrifolsPhase 3
37
ORX142 TabletsCentessa PharmaceuticalsPhase 1
33